Grant: Fellowship - Priority Announcement: Orphan Drug Policy
University of British Columbia
$25,000.00
Evaluating the Impact of Moral Arguments on Societal Values for Orphan Drug Coverage
FY 2012-13
Summary
Orphan drugs for rare diseases are often very expensive, with the cost of treating a single patient reaching up to $1 million per year. These drugs rarely meet the usual thresholds for efficacy or cost-effectiveness used in health technology assessment, however, which poses a moral dilemma for policy-makers, since the same funds used to treat one individual with a rare disease could provide less costly medications for many more Canadians. Since taxpayers must ultimately bear the costs of funding these treatments through the public insurance system, empirically estimating society's willingness to pay for expensive treatments for rare diseases, despite the significant opportunity costs, is a key element of democratic decision-making in this area. Using an online survey of 3,000 Canadians, we will explore societal preferences for orphan drug funding by presenting respondents with different scenarios in which provincial health authorities must decide whether or not to fund a specific treatment through the provincial insurance system. The scenarios will vary based on characteristics like the cost of the treatment, the severity and prevalence of the disease it targets, and, crucially, the types of arguments used by proponents and opponents of funding that particular treatment. This survey will provide an estimate of societal willingness to pay for the treatment of rare diseases under conditions that approximate the real-world context in which Canadians might learn about the policy challenge posed by orphan drugs. Knowledge generated will facilitate more informed orphan drug policy decisions consistent with the value that society places on the treatment of rare diseases.
Department
Program
Fellowship - Priority Announcement: Orphan Drug Policy
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
284337
Name
Dragojlovic Nicolas
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Pfizer Canada Inc. (Quebec)
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Research Training A - Post-PhD (HTA)
Projecttitle
Evaluating the Impact of Moral Arguments on Societal Values for Orphan Drug Coverage
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Orphan Drug Policy
Keyworddelim
Communication; Discrete Choice Experiment; Drug Coverage; Health Policy; Moral Dilemma; Orphan Drugs; Prescription Drugs Policy; Rare Diseases; Societal Values; Survey Research
Abstract
Orphan drugs for rare diseases are often very expensive, with the cost of treating a single patient reaching up to $1 million per year. These drugs rarely meet the usual thresholds for efficacy or cost-effectiveness used in health technology assessment, however, which poses a moral dilemma for policy-makers, since the same funds used to treat one individual with a rare disease could provide less costly medications for many more Canadians. Since taxpayers must ultimately bear the costs of funding these treatments through the public insurance system, empirically estimating society's willingness to pay for expensive treatments for rare diseases, despite the significant opportunity costs, is a key element of democratic decision-making in this area. Using an online survey of 3,000 Canadians, we will explore societal preferences for orphan drug funding by presenting respondents with different scenarios in which provincial health authorities must decide whether or not to fund a specific treatment through the provincial insurance system. The scenarios will vary based on characteristics like the cost of the treatment, the severity and prevalence of the disease it targets, and, crucially, the types of arguments used by proponents and opponents of funding that particular treatment. This survey will provide an estimate of societal willingness to pay for the treatment of rare diseases under conditions that approximate the real-world context in which Canadians might learn about the policy challenge posed by orphan drugs. Knowledge generated will facilitate more informed orphan drug policy decisions consistent with the value that society places on the treatment of rare diseases.
Competitiondate
201302
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dragojlovic, Nicolas
Approvedterm
2 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $25,000~ $0~